388 related articles for article (PubMed ID: 22961620)
1. Overexpression of human wild-type FUS causes progressive motor neuron degeneration in an age- and dose-dependent fashion.
Mitchell JC; McGoldrick P; Vance C; Hortobagyi T; Sreedharan J; Rogelj B; Tudor EL; Smith BN; Klasen C; Miller CC; Cooper JD; Greensmith L; Shaw CE
Acta Neuropathol; 2013 Feb; 125(2):273-88. PubMed ID: 22961620
[TBL] [Abstract][Full Text] [Related]
2. Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis.
Verbeeck C; Deng Q; Dejesus-Hernandez M; Taylor G; Ceballos-Diaz C; Kocerha J; Golde T; Das P; Rademakers R; Dickson DW; Kukar T
Mol Neurodegener; 2012 Oct; 7():53. PubMed ID: 23046583
[TBL] [Abstract][Full Text] [Related]
3. Wild type human TDP-43 potentiates ALS-linked mutant TDP-43 driven progressive motor and cortical neuron degeneration with pathological features of ALS.
Mitchell JC; Constable R; So E; Vance C; Scotter E; Glover L; Hortobagyi T; Arnold ES; Ling SC; McAlonis M; Da Cruz S; Polymenidou M; Tessarolo L; Cleveland DW; Shaw CE
Acta Neuropathol Commun; 2015 Jun; 3():36. PubMed ID: 26108367
[TBL] [Abstract][Full Text] [Related]
4. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients.
Collins M; Riascos D; Kovalik T; An J; Krupa K; Krupa K; Hood BL; Conrads TP; Renton AE; Traynor BJ; Bowser R
Acta Neuropathol; 2012 Nov; 124(5):717-32. PubMed ID: 22993125
[TBL] [Abstract][Full Text] [Related]
5. Transportin 1 colocalization with Fused in Sarcoma (FUS) inclusions is not characteristic for amyotrophic lateral sclerosis-FUS confirming disrupted nuclear import of mutant FUS and distinguishing it from frontotemporal lobar degeneration with FUS inclusions.
Troakes C; Hortobágyi T; Vance C; Al-Sarraj S; Rogelj B; Shaw CE
Neuropathol Appl Neurobiol; 2013 Aug; 39(5):553-61. PubMed ID: 22934812
[TBL] [Abstract][Full Text] [Related]
6. Stepwise acquirement of hallmark neuropathology in FUS-ALS iPSC models depends on mutation type and neuronal aging.
Japtok J; Lojewski X; Naumann M; Klingenstein M; Reinhardt P; Sterneckert J; Putz S; Demestre M; Boeckers TM; Ludolph AC; Liebau S; Storch A; Hermann A
Neurobiol Dis; 2015 Oct; 82():420-429. PubMed ID: 26253605
[TBL] [Abstract][Full Text] [Related]
7. FUS pathology in basophilic inclusion body disease.
Munoz DG; Neumann M; Kusaka H; Yokota O; Ishihara K; Terada S; Kuroda S; Mackenzie IR
Acta Neuropathol; 2009 Nov; 118(5):617-27. PubMed ID: 19830439
[TBL] [Abstract][Full Text] [Related]
8. FUS(1-359) transgenic mice as a model of ALS: pathophysiological and molecular aspects of the proteinopathy.
Funikov SY; Rezvykh AP; Mazin PV; Morozov AV; Maltsev AV; Chicheva MM; Vikhareva EA; Evgen'ev MB; Ustyugov AA
Neurogenetics; 2018 Aug; 19(3):189-204. PubMed ID: 29982879
[TBL] [Abstract][Full Text] [Related]
9. A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies.
Lashley T; Rohrer JD; Bandopadhyay R; Fry C; Ahmed Z; Isaacs AM; Brelstaff JH; Borroni B; Warren JD; Troakes C; King A; Al-Saraj S; Newcombe J; Quinn N; Ostergaard K; Schrøder HD; Bojsen-Møller M; Braendgaard H; Fox NC; Rossor MN; Lees AJ; Holton JL; Revesz T
Brain; 2011 Sep; 134(Pt 9):2548-64. PubMed ID: 21752791
[TBL] [Abstract][Full Text] [Related]
10. Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations.
Neumann M; Valori CF; Ansorge O; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ishihara K; Ang LC; Bilbao JM; Mackenzie IR
Acta Neuropathol; 2012 Nov; 124(5):705-16. PubMed ID: 22842875
[TBL] [Abstract][Full Text] [Related]
11. Aggressive FUS-Mutant Motor Neuron Disease Without Profound Spinal Cord Pathology.
Wongworawat YC; Liu YA; Raghavan R; White CL; Dietz R; Zuppan C; Rosenfeld J
J Neuropathol Exp Neurol; 2020 Apr; 79(4):365-369. PubMed ID: 32142142
[TBL] [Abstract][Full Text] [Related]
12. FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations.
Neumann M; Bentmann E; Dormann D; Jawaid A; DeJesus-Hernandez M; Ansorge O; Roeber S; Kretzschmar HA; Munoz DG; Kusaka H; Yokota O; Ang LC; Bilbao J; Rademakers R; Haass C; Mackenzie IR
Brain; 2011 Sep; 134(Pt 9):2595-609. PubMed ID: 21856723
[TBL] [Abstract][Full Text] [Related]
13. Neuronal dysfunction caused by FUSR521G promotes ALS-associated phenotypes that are attenuated by NF-κB inhibition.
Pelaez MC; Desmeules A; Gelon PA; Glasson B; Marcadet L; Rodgers A; Phaneuf D; Pozzi S; Dutchak PA; Julien JP; Sephton CF
Acta Neuropathol Commun; 2023 Nov; 11(1):182. PubMed ID: 37974279
[TBL] [Abstract][Full Text] [Related]
14. Behavioural impairments in mice of a novel FUS transgenic line recapitulate features of frontotemporal lobar degeneration.
Lysikova EA; Kukharsky MS; Chaprov KD; Vasilieva NA; Roman AY; Ovchinnikov RK; Deykin AV; Ninkina N; Buchman VL
Genes Brain Behav; 2019 Nov; 18(8):e12607. PubMed ID: 31437340
[TBL] [Abstract][Full Text] [Related]
15. ALS-FUS pathology revisited: singleton FUS mutations and an unusual case with both a FUS and TARDBP mutation.
King A; Troakes C; Smith B; Nolan M; Curran O; Vance C; Shaw CE; Al-Sarraj S
Acta Neuropathol Commun; 2015 Oct; 3():62. PubMed ID: 26452761
[TBL] [Abstract][Full Text] [Related]
16. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration.
Wils H; Kleinberger G; Janssens J; Pereson S; Joris G; Cuijt I; Smits V; Ceuterick-de Groote C; Van Broeckhoven C; Kumar-Singh S
Proc Natl Acad Sci U S A; 2010 Feb; 107(8):3858-63. PubMed ID: 20133711
[TBL] [Abstract][Full Text] [Related]
17. FUS transgenic rats develop the phenotypes of amyotrophic lateral sclerosis and frontotemporal lobar degeneration.
Huang C; Zhou H; Tong J; Chen H; Liu YJ; Wang D; Wei X; Xia XG
PLoS Genet; 2011 Mar; 7(3):e1002011. PubMed ID: 21408206
[TBL] [Abstract][Full Text] [Related]
18. Fused in sarcoma (FUS) protein lacking nuclear localization signal (NLS) and major RNA binding motifs triggers proteinopathy and severe motor phenotype in transgenic mice.
Shelkovnikova TA; Peters OM; Deykin AV; Connor-Robson N; Robinson H; Ustyugov AA; Bachurin SO; Ermolkevich TG; Goldman IL; Sadchikova ER; Kovrazhkina EA; Skvortsova VI; Ling SC; Da Cruz S; Parone PA; Buchman VL; Ninkina NN
J Biol Chem; 2013 Aug; 288(35):25266-25274. PubMed ID: 23867462
[TBL] [Abstract][Full Text] [Related]
19. Atypical FTLD-FUS associated with ALS-TDP: a case report.
Kobayashi Z; Arai T; Yokota O; Tsuchiya K; Hosokawa M; Oshima K; Niizato K; Akiyama H; Mizusawa H
Neuropathology; 2013 Feb; 33(1):83-6. PubMed ID: 22640227
[TBL] [Abstract][Full Text] [Related]
20. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43.
Walker AK; Spiller KJ; Ge G; Zheng A; Xu Y; Zhou M; Tripathy K; Kwong LK; Trojanowski JQ; Lee VM
Acta Neuropathol; 2015 Nov; 130(5):643-60. PubMed ID: 26197969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
